These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17059378)

  • 1. Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs.
    de Francisco AL
    Expert Opin Pharmacother; 2006 Nov; 7(16):2215-24. PubMed ID: 17059378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for secondary hyperparathyroidism.
    Cozzolino M; Tomlinson J; Walsh L; Bellasi A
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):197-208. PubMed ID: 25702624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The need for better control of secondary hyperparathyroidism.
    Locatelli F
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
    Ogata H; Koiwa F; Ito H; Kinugasa E
    Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?
    Wetmore JB; Quarles LD
    Nat Clin Pract Nephrol; 2009 Jan; 5(1):24-33. PubMed ID: 18957950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to treatment of secondary hyperparathyroidism.
    Locatelli F; Limardo M; Pontoriero G
    Curr Opin Investig Drugs; 2008 Apr; 9(4):363-70. PubMed ID: 18393103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
    Quarles LD
    Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
    Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone health and vascular calcification relationships in chronic kidney disease.
    Spasovski GB
    Int Urol Nephrol; 2007; 39(4):1209-16. PubMed ID: 17899431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism].
    Tanaka H; Komaba H; Fukagawa M
    Clin Calcium; 2011 Nov; 21(11):27-34. PubMed ID: 22040818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.